206 related articles for article (PubMed ID: 7640218)
1. Prognostic value of bcl-2 expression in invasive breast cancer.
Hellemans P; van Dam PA; Weyler J; van Oosterom AT; Buytaert P; Van Marck E
Br J Cancer; 1995 Aug; 72(2):354-60. PubMed ID: 7640218
[TBL] [Abstract][Full Text] [Related]
2. Bcl-2 expression is associated with lymph node metastasis in human ductal breast carcinoma.
Sierra A; Lloveras B; Castellsagué X; Moreno L; García-Ramirez M; Fabra A
Int J Cancer; 1995 Jan; 60(1):54-60. PubMed ID: 7814152
[TBL] [Abstract][Full Text] [Related]
3. Expression of Bcl-2 in node-negative breast cancer is associated with various prognostic factors, but does not predict response to one course of perioperative chemotherapy.
van Slooten HJ; Clahsen PC; van Dierendonck JH; Duval C; Pallud C; Mandard AM; Delobelle-Deroide A; van de Velde CJ; van de Vijver MJ
Br J Cancer; 1996 Jul; 74(1):78-85. PubMed ID: 8679463
[TBL] [Abstract][Full Text] [Related]
4. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
[TBL] [Abstract][Full Text] [Related]
5. Can expression of apoptosis genes, bcl-2 and bax, predict survival and responsiveness to chemotherapy in node-negative breast cancer patients?
Kymionis GD; Dimitrakakis CE; Konstadoulakis MM; Arzimanoglou I; Leandros E; Chalkiadakis G; Keramopoulos A; Michalas S
J Surg Res; 2001 Aug; 99(2):161-8. PubMed ID: 11469882
[TBL] [Abstract][Full Text] [Related]
6. Clinical relevance of immunohistochemical expression of p53-targeted gene products mdm-2, p21 and bcl-2 in breast carcinoma.
Bánkfalvi A; Tory K; Kemper M; Breukelmann D; Cubick C; Poremba C; Füzesi L; Lellè RJ; Böcker W
Pathol Res Pract; 2000; 196(7):489-501. PubMed ID: 10926327
[TBL] [Abstract][Full Text] [Related]
7. Correlation between genetic and biological aspects in primary non-metastatic breast cancers and corresponding synchronous axillary lymph node metastasis.
D'Andrea MR; Limiti MR; Bari M; Zambenedetti P; Montagutti A; Ricci F; Pappagallo GL; Sartori D; Vinante O; Mingazzini PL
Breast Cancer Res Treat; 2007 Mar; 101(3):279-84. PubMed ID: 16835704
[TBL] [Abstract][Full Text] [Related]
8. Prognostic indicators for breast cancer patients with one to three regional lymph node metastases, with special reference to alterations in expression levels of bcl-2, p53 and c-erbB-2 proteins.
Zhang GJ; Tsuda H; Adachi I; Fukutomi T; Yamamoto H; Hirohashi S
Jpn J Clin Oncol; 1997 Dec; 27(6):371-7. PubMed ID: 9437997
[TBL] [Abstract][Full Text] [Related]
9. Biological indicators of aggressiveness in T1 ductal invasive breast cancer.
Bucci B; Carico E; Rinaldi A; Froio F; Puce YM; D'Agnano I; Vecchione A; Brunetti E
Anticancer Res; 2001; 21(4B):2949-55. PubMed ID: 11712792
[TBL] [Abstract][Full Text] [Related]
10. The prevalence of BCL-2 immunoreactivity in breast carcinomas and its clinicopathological correlates, with particular reference to oestrogen receptor status.
Doglioni C; Dei Tos AP; Laurino L; Chiarelli C; Barbareschi M; Viale G
Virchows Arch; 1994; 424(1):47-51. PubMed ID: 7981903
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of glutathione S-transferase-pi in invasive breast cancer.
Huang J; Tan PH; Thiyagarajan J; Bay BH
Mod Pathol; 2003 Jun; 16(6):558-65. PubMed ID: 12808061
[TBL] [Abstract][Full Text] [Related]
12. BCL-6 oncoprotein in breast cancer: loss of expression in disease progression.
Pinto AE; André S; Silva G; Vieira S; Santos AC; Dias S; Soares J
Pathobiology; 2009; 76(5):235-42. PubMed ID: 19816083
[TBL] [Abstract][Full Text] [Related]
13. Prognostic relevance of carcinoembryonic antigen and estrogen receptor status in breast cancer patients.
Esteban JM; Felder B; Ahn C; Simpson JF; Battifora H; Shively JE
Cancer; 1994 Sep; 74(5):1575-83. PubMed ID: 7914825
[TBL] [Abstract][Full Text] [Related]
14. The relationship between expression of p53/Bcl-2 and histopathological criteria in breast invasive ductal carcinomas.
Gursan N; Karakök M; Sari I; Gursan MS
Int J Clin Pract; 2001 Nov; 55(9):589-90. PubMed ID: 11770353
[TBL] [Abstract][Full Text] [Related]
15. bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer.
Leek RD; Kaklamanis L; Pezzella F; Gatter KC; Harris AL
Br J Cancer; 1994 Jan; 69(1):135-9. PubMed ID: 8286195
[TBL] [Abstract][Full Text] [Related]
16. Mitochondrial UCP4 and bcl-2 expression in imprints of breast carcinomas: relationship with DNA ploidy and classical prognostic factors.
Gonidi M; Athanassiadou AM; Patsouris E; Tsipis A; Dimopoulos S; Kyriakidou V; Chelidonis G; Athanassiadou P
Pathol Res Pract; 2011 Jun; 207(6):377-82. PubMed ID: 21621926
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of Bcl-2 in invasive breast cancer receiving chemotherapy and endocrine therapy.
Yang Q; Sakurai T; Yoshimura G; Suzuma T; Umemura T; Nakamura M; Nakamura Y; Mori I; Kakudo K
Oncol Rep; 2003; 10(1):121-5. PubMed ID: 12469156
[TBL] [Abstract][Full Text] [Related]
18. Expression of death-related genes and their relationship to loss of apoptosis in T1 ductal breast carcinomas.
Sierra A; Castellsagué X; Coll T; Mañas S; Escobedo A; Moreno A; Fabra A
Int J Cancer; 1998 Apr; 79(2):103-10. PubMed ID: 9583721
[TBL] [Abstract][Full Text] [Related]
19. Image cytometric bcl-2:bax and bcl-2:bcl-x ratios in invasive breast carcinoma: correlation with prognosis.
Schiller AB; Clark WS; Cotsonis G; Lawson D; DeRose PB; Cohen C
Cytometry; 2002 Aug; 50(4):203-9. PubMed ID: 12210599
[TBL] [Abstract][Full Text] [Related]
20. [Proliferation index and its prognostic value in invasive ductal breast carcinoma].
Falco M
Ann Acad Med Stetin; 2009; 55(1):22-30. PubMed ID: 20349588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
